| Literature DB >> 29104378 |
Anne Ladwig1, Helene Luise Walter1, Jörg Hucklenbroich1, Antje Willuweit2, Karl-Josef Langen2, Gereon Rudolph Fink1,3, Maria Adele Rueger1,3, Michael Schroeter1,3.
Abstract
BACKGROUND: Focal cerebral ischemia induces distinct neuroinflammatory processes. We recently reported the extracellular phosphor-glyco-protein osteopontin (OPN) to directly affect primary microglia in vitro, promoting survival while shifting their inflammatory profile towards a more neutral phenotype. We here assessed the effects of OPN on microglia after stroke in vivo, with focus on infarct demarcation.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29104378 PMCID: PMC5632451 DOI: 10.1155/2017/7189421
Source DB: PubMed Journal: Mediators Inflamm ISSN: 0962-9351 Impact factor: 4.711
Details of primary antibodies.
| Antibody | Antigene | Dilution/fixation | Identified cell type | Reference, company |
|---|---|---|---|---|
| Anti-NeuN | Neuronal nuclear antigen (DNA-binding) | 1 : 2000 4% PFA, | Surviving neurons | Anti-NeuN monoclonal antibody, mouse, catalog number MAB377, Merck Millipore |
| Anti-Iba1 | Ionized calcium binding adaptor molecule 1 | 1 : 1000, 4% PFA, | Activated microglia/macrophages | Anti-iba1 polyclonal antibody, rabbit, catalog number 019-19741, Wako Chemicals |
| Anti-iNOS | Inducible NO-synthetase | 1 : 100, 4% PFA, | M1-polarized microglia | Anti-iNOS polyclonal antibody, rabbit, catalog number ab15323, abcam |
| Anti-Arg1 | Arginase 1 | 1 : 1000 4% PFA, | M2-polarized microglia | Anti-liver-arginase polyclonal antibody, goat, catalog number ab60176, abcam |
| Anti-CD206 | Mannose receptor | 1 : 1500, 4% PFA, | M2-polarized microglia | Anti-CD206 polyclonal antibody, goat, catalog number AF2535, R&D Systems |
| Anti-Ym1 | Chitinase-3-like-3 | 1 : 100, 50% acetone | M2-polarized microglia | Anti-Ym1 polyclonal, rabbit, catalog number 01404, Stemcell Technologies |
| Anti-vWF | von Willebrand factor | 1 : 1500, 4% PFA, | Endothelial cells | Anti-vWF polyclonal antibody, rabbit, catalog number ab6994, abcam |
| Anti-NG2 | Chondroitin sulfate proteoglycan | 1 : 4000, 100% acetone | Polydendrocytes | Anti-NG2 polyclonal antibody, rabbit, catalog number AB5320, Millipore |
| Anti-GFAP | Glial fibrillary acidic protein | 1 : 2000, 4% PFA | Astrocytes | Anti-GFAP monoclonal antibody, mouse, catalog number MAB360, Millipore |
Figure 1OPN treatment shifts the M1/M2 balance towards an M2 phenotype. (a) Arg1+ M2 cells (red) dominated the infarcted area in OPN-treated rats, whereas iNOS+ M1 microglia were found predominantly in vehicle-treated animals (green). (b) M1 (iNOS-expressing) microglia and M2 (Arg+, CD206+, or Ym1+) microglia in the infarcted area after photothrombosis expressed as M1/M2 ratio. Ten days after photothrombosis, the ratios of M1/M2 microglia were significantly decreased in OPN-treated animals compared to vehicle-treated controls, suggesting an increase in M2 polarization. (c) Close-up of microglia expressing either M1 (iNOS) or M2 (Arg1) markers (upper row), or expressing both markers (lower row). Scale bars represent 40 μm in (a) and 10 μm (c). All graphs show mean and SD; ∗p < 0.05.
Figure 2OPN increases functional layering of microglia subtypes and influences the relative size of distinct infarct subareas. (a) Cresyl violet staining of the photothrombotic infarct. The infarct area could be subdivided into five zones according to distribution pattern of inflammatory cells: hypocellular infarct core (1), cell-rich infarct margin (2), demarcation zone (3), peri-infarct zone (4), and unaffected tissue (5). (b) The size of the evaluated infarct area shows a trend towards smaller infarcts, but no significant changes under OPN treatment. The infarct layers, especially those close to the core show significant changes. The size of the hypocellular core is significantly reduced post OPN and the infarct margin is proportionally larger. (c) Displays pseudocoloured images of exemplary photothrombotic infarcts. Sections were stained for Arg1 (yellow), CD206 (orange), YM1 (red), iNOS (green), Iba1 (blue), and vWF (purple). Adjacent sections of an OPN-treated animal (right column) and a control rat (left column). Scale bars represent 300 μm (c). All graphs show mean and SD; ∗p < 0.05.
Figure 3OPN modulates the infiltration of microglia subpopulations into distinct infarct subareas (part I: Iba1 and iNOS). All microglia stained with Iba1+ (a) and proinflammatory microglia stained with iNOS (b) shown in distinct subareas of the photothrombotic infarct after OPN treatment compared to control. Iba1+ cells are found elevated the outer infarct core, while iNOS+ cells (M1) are decreased in the infarct margin and the demarcation zone in OPN-treated animals. Scale bars represent 50 μm. All graphs show mean and SD; ∗p < 0.05; ∗∗∗p < 0.001.
Figure 4OPN modulates the infiltration of microglia subpopulations into distinct infarct subareas (part II: Arg1 and Ym1). M2 subpopulations stained with Arg1 and Ym1 in subareas of photothrombotic infarct after OPN compared to placebo treatment. Arg1+ microglia show an increase in the outer infarct core, while Ym1+ microglia are found enriched in the outer core and infarct margin. Scale bars represent 50 μm. All graphs show mean and SD; ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001.
Figure 5OPN polarizes astrocytes towards the infarct. (a) Infarct margin stained for GFAP showing the majority of astrocytes with processes aligned towards the infarct core in OPN-treated animals, and increased process length in OPN-treated animals. Quantification of changes in polarisation (b) and process length (c). All graphs show mean and SD. ∗p < 0.05; ∗∗∗p < 0.001.